ich habe gerade einen Bericht auf Englisch gefunden, leider sind meine Sprachkenntinise hierzu nicht ausreichend.
Vl kann mir jemand sinngemäß wiedergeben wie die Ergebnisse in diesem Bericht waren.
sehe ich das richtig das zwischen Placebo und BG12 so gut wie kein Unterschiede ist?
Quelle:http://www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/P07.102
Results: Overall, 1234 patients enrolled and received study treatment. At 2 years, patients reported higher mean SF-36 PCS scores with BG-12 BID (43.4) and TID (44.2) versus placebo (41.9; P<0.001 for both), indicating an improvement in the assessment of physical well-being. Similar trends were observed on SF-36 MCS scores (placebo [44.6] versus BG-12 BID [45.5] and TID [46.1]; P=0.065 and P<0.002, respectively). Over time, most individual domain scores revealed a significant treatment effect for BG-12 BID at 6, 12, and 24 months. The proportion of patients who achieved clinically important improvements in PCS and MCS scores (≥5-point change) was significantly higher in the BG-12 groups versus placebo (P<0.05).
Conclusions: Together with the significant effects on clinical measures (reduced relapse risk, annualized relapse rate, and disability progression), the demonstrated benefits on patient-reported health-related QoL further supports a potential role for BG-12 as a valuable oral treatment option in RRMS patients.
mit freundlichen Grüßen und vielen Dank!
Erol